

- Higashi, G. I. & Farid, Z. (1979). Oxamniquine fever drug-induced or immune-complex reaction? *British Medical Journal*, **6**, 830.
- Katz, N., Coelho, P. M. Z. & Pellegrino, J. (1970). Evaluation of Kato's quantitative method through the recovery of *Schistosoma mansoni* eggs added to human faeces. *Journal of Parasitology*, **56**, 1032-1033.
- Katz, N., Chaves, A. & Pellegrino, J. (1972). A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni. *Revista do Instituto de Medicina Tropical de São Paulo*, **14**, 397-402.
- Kaye, B. & Woolhouse, N. M. (1976). The metabolism of oxamniquine, a new schistosomicide. *Annals of Tropical Medicine and Parasitology*, **70**, 323-328.
- Magalhães Filho, A. (1952). Anatomia patológica da esquistossomose mansoni. In: *Esquistossomose mansoni no Brasil. (Doença de Manson-Pirajá da Silva)*. São Paulo: Sociedade de Gastroenterologia e Nutrição de São Paulo, pp. 125-132.
- Magalhães Filho, A. (1955). Patologia da esquistossomose mansônica. Considerações sobre a ação patogênica do verme morto. *An. Fac. Med. Univ. Recife*, **15**, 95-110.
- Metzger, L. F., Altose, M. D. & Fishman, A. P. (1980). *Evaluation of Pulmonary Diseases and Disorders*. New York: McGraw-Hill, pp. 1751-1777.
- Mota-Santos, T. A., Tavares, C. A. P., Gazzinelli, G. & Pellegrino, J. (1977). Immunosuppression mediated by adult worms in chronic schistosomiasis mansoni. *American Journal of Tropical Medicine and Hygiene*, **26**, 727-731.
- Pedroso, E. R. P. (1982). *Contribuição ao estudo da esquistossomose mansoni humana e experimental. Especial referência às alterações clínico-radiológicas do pulmão após tratamento específico. Pulmão modelo imunopatológico da doença esquistossomótica*. Thesis, Faculty of Medicine, University Federal de Minas Gerais, Belo Horizonte.
- Prata, A. & Machado, R. (1960). Alterações pulmonares observadas no tratamento antimonial da esquistossomose. *Revista do Instituto de Medicina Tropical de São Paulo*, **2**, 29-36.
- Sette, H. (1953). *O tratamento da esquistossomose mansoni à luz da patologia hepática*. Doctorate thesis, University Federal, Recife.
- Silva, L. C., Sette, H. Jr, Chamone, D. A. F., Albuquerque, A. S., Punksas, J. A. & Raia, S. (1974). Estudos clínicos com a oxamniquine (UK-4271) administrada oralmente para o tratamento da esquistossomose mansônica. *Revista do Instituto de Medicina Tropical de São Paulo*, **16**, 103-109.
- Silva, L. C., Sette, H., Jr, Christo, C., Sette, P. C. & Kaye, B. (1980). Níveis séricos e eficácia da oxamniquine em portadores da esquistossomose mansoni após administração de uma dose terapêutica. *Revista do Instituto de Medicina Tropical de São Paulo*, **22**, 175-181.

Accepted for publication 21 July 1986

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (1987) **81**, 781

Short Report

Mebendazole in the treatment of *Schistosoma haematobium*

NOORI S. AL-WAILI

Private Clinic, House 34, Street 42, Section 729, Al-Mashtel, New Baghdad, Baghdad, Iraq

Mebendazole is a broad spectrum antihelminthic drug used in treating patients infected with various species of helminths. It is active against both gastrointestinal and tissue-stage helminths and is well tolerated in the high doses needed to kill the latter. This report concerns two cases of *Schistosoma haematobium* infection treated with mebendazole.

Both patients were male; one was 30 years old and the other was 25. They presented with recent onset of lower abdominal pain, dysuria and frequent terminal haematuria. Physical examination showed suprapubic tenderness. Urine analysis revealed abundant red blood cells and *S. haematobium* eggs. After informed consent the patients were treated with 1 gram per day of mebendazole orally, given in two equally divided doses; they were advised to attend the clinic daily for follow-up (physical examination and urine analysis) and to report any side effects. Urine analysis showed a great reduction in the number of *S. haematobium* eggs at 3-5 days and eggs were not detectable by 10 days after the commencement of treatment. All clinical symptoms disappeared within 2 weeks. No side effect was noted and at six months follow-up the patients' condition was normal.

Schistosomiasis is one of the most important helminth disease because of its worldwide distribution and the serious pathological changes produced by the parasite and eggs. Urinary schistosomiasis is endemic in Iraq (HAMAMI, 1960). Our recent report suggested a role for schistosomiasis in the aetiology of bladder cancer and the importance of preventive measures

(AL-ANI & AL-WAILI, 1985). The control of schistosomiasis relies largely on population-based chemotherapy and repeated drug administration to infected individuals. Older drugs used in the treatment of schistosomiasis have considerable side effects and, although safe, effective drugs such as praziquantel and metrifonate have become available, differences in drug susceptibilities and the possible development of drug resistance made a trial of the less toxic drug, mebendazole, advisable.

Mebendazole may be not only active against schistosomiasis but may also stimulate humoral and cell-mediated immunity as happens with other helminthiasis treated by mebendazole (KAMATH *et al.*, 1985). The high dose of mebendazole used in this trial was not associated with side effects and it has been shown that doses as high as 150 mg/kg/day of mebendazole are safe at least for short periods (CAMPBELL *et al.*, 1974).

Although this study showed the value of mebendazole in the treatment of schistosomiasis, it is too early to reach any firm conclusion and other trials with larger numbers of patients are required.

References

- Al-Ani, M. & Al-Waili, N. (1985). Bladder cancer and urinary schistosomiasis in patients with haematuria and chronic bladder symptoms. *Saudi Medical Journal*, **6**, 554-560.
- Campbell, W., McCracken, R., Blair, L. & Ramway, N. (1974). Therapy of hydatid disease. *Journal of the American Medical Association*, **230**, 825-830.
- Hamami, A. (1960). Bilharziasis control problems in Iraq. *Bulletin of Endemic Disease*, **3**, 1-14.
- Kamath, V., Bhopale, M. & Bhide, M. (1985). Immunological evidence of chemotherapeutic action of mebendazole against *Ancylostoma ceylanicum* (Looss, 1911) in hamster (*Mesocricetus auratus*). *Journal of Helminthology*, **59**, 195-199.

Accepted for publication 19 December 1986